XNASPBLA
Market cap1mUSD
Dec 24, Last price
0.34USD
1D
5.98%
1Q
1.30%
IPO
-100.00%
Name
Panbela Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
180.33%
Rev. gr., 5y
%
Revenues
0k
Net income
-25m
L-27.68%
CFO
-25m
L+65.29%
Earnings
Mar 24, 2025
Profile
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
IPO date
Jul 29, 2014
Employees
6
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 51,294 | 69,824 | 20,020 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (51,294) | (69,824) | (20,020) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (186) | (116) | (488) | |||||||
Tax Rate | ||||||||||
NOPAT | (51,108) | (69,708) | (19,532) | |||||||
Net income | (25,263) -27.68% | (34,933) 244.68% | (10,135) 112.56% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 23,053 | 5,349 | 9,054 | |||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | 1,000 | 1,650 | ||||||||
Long-term debt | 4,194 | 5,194 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | 2,616 | 5,559 | (11,867) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (25,249) | (15,276) | (6,704) | |||||||
CAPEX | (660) | |||||||||
Cash from investing activities | 400 | (656) | (540) | |||||||
Cash from financing activities | 26,142 | 5,354 | 10,095 | |||||||
FCF | (47,256) | (65,302) | (19,532) | |||||||
| Balance | ||||||||||
Cash | 2,578 | 1,285 | 11,867 | |||||||
Long term investments | ||||||||||
Excess cash | 2,578 | 1,285 | 11,867 | |||||||
Stockholders' equity | (124,752) | (90,334) | (56,015) | |||||||
Invested Capital | 125,236 | 89,129 | 66,227 | |||||||
ROIC | ||||||||||
ROCE | 5,794.52% | |||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | 18.30 -98.96% | 1,759.20 -95.76% | 41,522.40 -51.40% | |||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | (51,294) | (69,824) | (20,020) | |||||||
EV/EBITDA | ||||||||||
Interest | 317 | 288 | 11 | |||||||
Interest/NOPBT | ||||||||||